| Patrick C Fall, DO | |
|
1200 Old York Rd, Abington, PA 19001-3720 | |
| (215) 481-2000 | |
| Not Available |
| Full Name | Patrick C Fall |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 23 Years |
| Location | 1200 Old York Rd, Abington, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588638894 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | OS012296 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Doylestown Hospital | Doylestown, PA | Hospital |
| Hospital Of Univ Of Pennsylvania | Philadelphia, PA | Hospital |
| St Mary Medical Center | Langhorne, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Oxygen Oasis Hyperbaric Wellness Center, Llc | 2264653047 | 5 |
| Oxygen Therapurity, Llc | 2769604768 | 5 |
| Southeast Pa Pain Management, Ltd | 9830091537 | 10 |
News Archive
What do bad sleep habits and stiff blood vessels have in common? Nothing good, say scientists exploring what appears to be a direct connection between a circadian clock that isn't working as it should and an enzyme that promotes inflammation working overtime.
Buffalo Grove, Illinois-based specialty-oncology drug development company, Meridian Laboratories, Inc (Meridian) held a Type B Pre-Investigational New Drug (pre-IND) meeting with the FDA Center for Drug Evaluation Research, Division of Oncology Products on Wednesday January 23, 2013 to discuss its plan to commence clinical development of ML061, Meridian's lead product, as a treatment for various types of cancer.
Inner city children from poor families are much more likely to seek emergency care for asthma than their more affluent peers, finds research published ahead of print in Thorax.
Trevena Inc., a leader in the discovery of G-protein coupled receptor (GPCR) biased ligands announced today that it was awarded a $7.65 million Grand Opportunity (GO) Grant by the office of the director of the National Institutes of Health (NIH). This grant will further fund Trevena's work to identify and characterize functionally selective biased ligands for a wide range of GPCRs.
› Verified 1 days ago
| Entity Name | Southeast Pa Pain Management, Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396747531 PECOS PAC ID: 9830091537 Enrollment ID: O20040123000021 |
News Archive
What do bad sleep habits and stiff blood vessels have in common? Nothing good, say scientists exploring what appears to be a direct connection between a circadian clock that isn't working as it should and an enzyme that promotes inflammation working overtime.
Buffalo Grove, Illinois-based specialty-oncology drug development company, Meridian Laboratories, Inc (Meridian) held a Type B Pre-Investigational New Drug (pre-IND) meeting with the FDA Center for Drug Evaluation Research, Division of Oncology Products on Wednesday January 23, 2013 to discuss its plan to commence clinical development of ML061, Meridian's lead product, as a treatment for various types of cancer.
Inner city children from poor families are much more likely to seek emergency care for asthma than their more affluent peers, finds research published ahead of print in Thorax.
Trevena Inc., a leader in the discovery of G-protein coupled receptor (GPCR) biased ligands announced today that it was awarded a $7.65 million Grand Opportunity (GO) Grant by the office of the director of the National Institutes of Health (NIH). This grant will further fund Trevena's work to identify and characterize functionally selective biased ligands for a wide range of GPCRs.
› Verified 1 days ago
| Entity Name | Oxygen Oasis Hyperbaric Wellness Center, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003239054 PECOS PAC ID: 2264653047 Enrollment ID: O20141020001640 |
News Archive
What do bad sleep habits and stiff blood vessels have in common? Nothing good, say scientists exploring what appears to be a direct connection between a circadian clock that isn't working as it should and an enzyme that promotes inflammation working overtime.
Buffalo Grove, Illinois-based specialty-oncology drug development company, Meridian Laboratories, Inc (Meridian) held a Type B Pre-Investigational New Drug (pre-IND) meeting with the FDA Center for Drug Evaluation Research, Division of Oncology Products on Wednesday January 23, 2013 to discuss its plan to commence clinical development of ML061, Meridian's lead product, as a treatment for various types of cancer.
Inner city children from poor families are much more likely to seek emergency care for asthma than their more affluent peers, finds research published ahead of print in Thorax.
Trevena Inc., a leader in the discovery of G-protein coupled receptor (GPCR) biased ligands announced today that it was awarded a $7.65 million Grand Opportunity (GO) Grant by the office of the director of the National Institutes of Health (NIH). This grant will further fund Trevena's work to identify and characterize functionally selective biased ligands for a wide range of GPCRs.
› Verified 1 days ago
| Entity Name | Oxygen Therapurity, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962828673 PECOS PAC ID: 2769604768 Enrollment ID: O20141106001267 |
News Archive
What do bad sleep habits and stiff blood vessels have in common? Nothing good, say scientists exploring what appears to be a direct connection between a circadian clock that isn't working as it should and an enzyme that promotes inflammation working overtime.
Buffalo Grove, Illinois-based specialty-oncology drug development company, Meridian Laboratories, Inc (Meridian) held a Type B Pre-Investigational New Drug (pre-IND) meeting with the FDA Center for Drug Evaluation Research, Division of Oncology Products on Wednesday January 23, 2013 to discuss its plan to commence clinical development of ML061, Meridian's lead product, as a treatment for various types of cancer.
Inner city children from poor families are much more likely to seek emergency care for asthma than their more affluent peers, finds research published ahead of print in Thorax.
Trevena Inc., a leader in the discovery of G-protein coupled receptor (GPCR) biased ligands announced today that it was awarded a $7.65 million Grand Opportunity (GO) Grant by the office of the director of the National Institutes of Health (NIH). This grant will further fund Trevena's work to identify and characterize functionally selective biased ligands for a wide range of GPCRs.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Patrick C Fall, DO P.o. Box 8500-5365, Philadelphia, PA 19178-0001 Ph: (201) 804-2800 | Patrick C Fall, DO 1200 Old York Rd, Abington, PA 19001-3720 Ph: (215) 481-2000 |
News Archive
What do bad sleep habits and stiff blood vessels have in common? Nothing good, say scientists exploring what appears to be a direct connection between a circadian clock that isn't working as it should and an enzyme that promotes inflammation working overtime.
Buffalo Grove, Illinois-based specialty-oncology drug development company, Meridian Laboratories, Inc (Meridian) held a Type B Pre-Investigational New Drug (pre-IND) meeting with the FDA Center for Drug Evaluation Research, Division of Oncology Products on Wednesday January 23, 2013 to discuss its plan to commence clinical development of ML061, Meridian's lead product, as a treatment for various types of cancer.
Inner city children from poor families are much more likely to seek emergency care for asthma than their more affluent peers, finds research published ahead of print in Thorax.
Trevena Inc., a leader in the discovery of G-protein coupled receptor (GPCR) biased ligands announced today that it was awarded a $7.65 million Grand Opportunity (GO) Grant by the office of the director of the National Institutes of Health (NIH). This grant will further fund Trevena's work to identify and characterize functionally selective biased ligands for a wide range of GPCRs.
› Verified 1 days ago
Denise Mann, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-481-2000 | |
Patrick B Breen, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-481-2000 | |
Daniel Maloney, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-481-2000 | |
Dr. Patrick P Shum, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-481-8681 | |
Robert Louis Koniuta, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-481-2000 | |
Joshua Burdick-will, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-480-2000 | |
Dr. Naheed G Mohammed, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-481-2000 |